Pharmaceutical cocrystals: An emerging approach to physical property enhancement

被引:303
作者
Jones, William
Motherwell, Samuel
Trask, Andrew V.
机构
关键词
biomedical; crystal growth; crystaffine;
D O I
10.1557/mrs2006.206
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Pharmaceutical cocrystals are crystalline molecular complexes containing therapeutic molecules. They represent an emerging class of pharmaceutical materials offering the. prospect of optimized physical properties. This article highlights important opportunities and challenges associated with the design and synthesis of pharmaceutical cocrystals. Cocrystallization is first placed into context with the more established approaches to physical property optimization of polymorph, hydrate, and salt selection. A directed, intermolecular-interaction-based approach to cocrystal design is described. The enhancement of specific physical properties, such as dissolution rate and physical stability, is illustrated by summarizing several recent reports. Synthetic approaches to cocrystallization are considered; in particular, the selectivity and screening-related opportunities afforded by solid-state grinding and solvent-drop grinding methods are discussed. Finally, an outlook on future developments summarizes the growth potential in this field, especially with regard to targeted informatics-driven cocrystal screening approaches.
引用
收藏
页码:875 / 879
页数:5
相关论文
共 32 条
[1]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[2]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[3]  
[Anonymous], 1965, PHYS CHEM ORGANIC SO
[4]   Salt selection and optimisation procedures for pharmaceutical new chemical entities [J].
Bastin, RJ ;
Bowker, MJ ;
Slater, BJ .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :427-435
[5]  
Bernstein J., 2020, Polymorphism in Molecular Crystals, Vsecond
[6]  
Bighley L. D., 1996, ENCY PHARM TECHNOLOG, V13
[7]  
Byrn S.R., 1999, Solid State Chemistry of Drugs, VSecond
[8]   SELECTIVE FORMATION OF HYDROGEN-BONDED COCRYSTALS BETWEEN A SULFONAMIDE AND AROMATIC CARBOXYLIC-ACIDS IN THE SOLID-STATE [J].
CAIRA, MR ;
NASSIMBENI, LR ;
WILDERVANCK, AF .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1995, (12) :2213-2216
[9]   Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development [J].
Chemburkar, SR ;
Bauer, J ;
Deming, K ;
Spiwek, H ;
Patel, K ;
Morris, J ;
Henry, R ;
Spanton, S ;
Dziki, W ;
Porter, W ;
Quick, J ;
Bauer, P ;
Donaubauer, J ;
Narayanan, BA ;
Soldani, M ;
Riley, D ;
McFarland, K .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :413-417
[10]   Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids [J].
Childs, SL ;
Chyall, LJ ;
Dunlap, JT ;
Smolenskaya, VN ;
Stahly, BC ;
Stahly, GP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (41) :13335-13342